UBS Called Novo Nordisk a 'Value Trap.' Here's the Other Side of That Argument.

UBS analyst Michael Yee believes investors prefer Eli Lilly's growth story to Novo Nordisk's turnaround story. Yee sees Novo Nordisk turning its business around, but believes it could take some time.

The Motley Fool • Oct 9, 2026

GLP-1s could offer unexpected relief from back and knee pain, but doctors urge caution

Rapid weight loss can lead to issues with bone quality, particularly in older adults.

Market Watch • Oct 8, 2026

Can NVO's Semaglutide Push Create Growth Beyond Cardiometabolic Care?

Novo's semaglutide expansion into liver disease and other obesity-related conditions can unlock growth, but competition and clinical risks loom.

Zacks Investment Research • Oct 7, 2026

Novo Nordisk (NVO) Increases Despite Market Slip: Here's What You Need to Know

Novo Nordisk (NVO) reached $38.26 at the closing of the latest trading day, reflecting a +1.95% change compared to its last close.

Zacks Investment Research • Oct 7, 2026

Novo Nordisk Vs. Eli Lilly: Judged Against Big Pharma, Only One Needs A Premium

Novo Nordisk is rated Buy versus Hold for Eli Lilly, anchored by a compelling valuation discount to big pharma peers. NVO trades at ~11.2x 2027 earnings, a ~26% discount to peer median, despite consensus growth rates in line with peers and a robust yield. The investment case does not require a rerating; ~10% annual returns are achievable if current discounted valuations hold and yield continues.

Seeking Alpha • Oct 8, 2026

Novo Stock Is Down More Than 70% From Its Peak. Value Trap or Generational Buying Opportunity?

Novo Nordisk rose dramatically because investors were excited after it launched the first GLP-1 weight-loss drug. The company lost the lead in the emerging GLP-1 space to Eli Lilly.

The Motley Fool • Oct 7, 2026

Is Most-Watched Stock Novo Nordisk A/S (NVO) Worth Betting on Now?

Novo Nordisk (NVO) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Zacks Investment Research • Oct 6, 2026

Eli Lilly and vs. Novo Nordisk A/S: Which Healthcare Stock Is a Better Buy in 2026?

Eli Lilly and shows rapid expansion with metabolic health treatments and high revenue growth. Novo Nordisk A/S maintains a strong global footprint with deep expertise in diabetes and obesity care.

The Motley Fool • Oct 6, 2026

Novo's Denecimig BLA Review Delayed by FDA Facility Remediation Work

NVO's denecimig FDA review is delayed by manufacturing facility remediation, while no clinical efficacy or safety deficiencies were identified.

Zacks Investment Research • Oct 5, 2026

Better High-Yield Dividend Stock: Pfizer or Novo Nordisk?

Novo Nordisk is a leading GLP-1 company, but its portfolio beyond that is limited.  Pfizer hasn't entered the GLP-1 race yet, but the company has a diversified business and a long history of success.

The Motley Fool • Oct 4, 2026